A Randomized Phase III Trial of Intravesical BCG veRsus Intravesical Docetaxel and GEmcitabine Treatment in BCG Nave High-Grade Non-Muscle Invasive Bladder Cancer (BRIDGE)
Sponsor: |
NIH |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAU9032 |
U.S. Govt. ID: |
NCT05538663 |
Contact: |
Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
This study is being done to answer the following question: Can we lower the chance of your bladder cancer growing or spreading by using one type of chemotherapy instilled in the bladder, Gemcitabine and Docetaxel, instead of the usual therapy? The usual approach for patients who are not in a study is treatment with Transurethral surgery of bladder tumor (TURBT) followed by instillations of Bacillus Calmette-Guerin (BCG) immunotherapy into the bladder via a catheter. We are doing this study because we want to find out if this approach is better or worse than the usual approach for your bladder cancer.
Investigator
Andrew Lenis, MD
Are you at least 18 years old? |
Yes |
No |
Have you been diagnosed with bladder cancer? |
Yes |
No |
Are you able to make regularly scheduled visits to the clinic for treatment and examinations? |
Yes |
No |